DALLAS - s4story -- Lonestar Clinical Research is now enrolling participants for a clinical study in Dallas evaluating a new inhaler treatment for asthma. The study offers no-cost care, requires no insurance, and provides a chance for local residents to help shape the future of asthma treatment.

Asthma is a major health concern in the Dallas area, affecting nearly 1 in 10 residents. Each year, more than 8,000 emergency room visits in the Dallas region are linked to asthma-related complications.

"If you live with asthma, your experience matters," said Dr. Ebuh- principal investigator at Lonestar Clinical Research. "This study offers an opportunity to not only access potential new treatment options at no cost but also contribute to important research that could benefit others living with asthma in our community."

More on S For Story

• Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
• New Book: Your Field Guide to Shaping a Meaningful Future in the Intelligent Age
• Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
• Rising Conservative Star Jordan Brace Emerges as Influential Political Voice with Elite Washington Connections
• Conservative Latinos for PA Shaping the Future of Hispanic Community, Guest State Treasurer Stacy Garrity

Why This Study Matters:

• Asthma impacts thousands across Dallas
• A new inhaler is being evaluated for effectiveness and safety
• Your participation could help improve care for yourself and others
• No cost. No insurance needed. Compensation available.

To learn more about the study or find out if you qualify, visit https://joinlonestarasthmastudy.com/
or call Lonestar Clinical Research at 214-177-7722

About Lonestar Clinical Research
We strive to provide every volunteer with the best level of care. Our friendly, experienced, and knowledgeable staff members make sure that each patient is informed, comfortable, and satisfied with their participation in clinical research.